Back to search

PES-HORISONT-EU-PES Horisont Europa

A suite of automated eye examination tests to rapidly screen for neuro-ophthalmic disorders

Awarded: NOK 74,999

The leading causes of sight loss (e.g. glaucoma, diabetic retinopathy, AMD and cataract) constitute a significant public health concern, especially considering the aging population. Also, neurological diseases, are known to have ocular manifestations that often precede its conventional diagnosis. Advanced ocular imaging technologies are recognized as a valuable strategy for earlier diagnosis of these diseases, significantly improving patients’ quality of life and reducing the economic burden to healthcare systems. BT aims at introducing a revolutionary product in the market to automate and digitize eye tests, providing an accurate, reliable, intuitive, and cost-effective system for standard-of-care screening of neuro-ophthalmic diseases. The expected outcome of this project is the successful market launch, commercialization ramp-up and fast scale-up of BulbiCAM and BulbiHUB as a unique predictive diagnostic support tool for the early detection of neuro-ophthalmic diseases. The main barriers for BT going forward are related to market awareness, acceptance to end-users, product scale-up and competitors positioning. This project will enable BT to: 1) mature and refine BulbiCAM and BulbiHUB for early detection and predictive diagnosis of neuro-ophthalmic disorders; 2) demonstrate and validate the clinical performance and safety of BulbiCAM and BulbiHUB in a large clinical outset to reach certification; 3) prepare commercialization, fast scale-up and market roll-out of BulbiCAM and BulbiHUB. The EIC Accelerator program provides a unique opportunity for BT to showcase the potential of its technology and gain market intelligence that will ultimately lead to acceptance by end-users. The completion of the project objectives is important for ensuring a successful entrance to the market and commercialization of our disruptive solution for the early detection of neuro-ophthalmic disorders.

Funding scheme:

PES-HORISONT-EU-PES Horisont Europa